Hikma Pharmaceuticals Plc Annual Financial Report (1228F)
March 17 2022 - 6:00AM
UK Regulatory
TIDMHIK
RNS Number : 1228F
Hikma Pharmaceuticals Plc
17 March 2022
Hikma Pharmaceuticals PLC
(the 'Company')
Publication of 2021 Annual Report and Notice of AGM
LEI: 549300BNS685UXH4JI75
The Company will today publish on its website, www.hikma.com ,
the Annual Report for the year ended
31 December 2021 (the '2021 Annual Report').
Hard copy versions of the following documents will be sent to
those shareholders who have elected to receive paper
communication:
-- 2021 Annual Report
-- 2022 Notice of Annual General Meeting
In compliance with Listing Rule 9.6.1 of the UK Financial
Conduct Authority ('FCA'), the aforementioned documents will be
submitted to the FCA's Electronic Submission System and will be
available from the National Storage Mechanism
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
This announcement is not a substitute for reading the 2021
Annual Report in full.
Peter Speirs
Company Secretary
17 March 2022
About Hikma
Hikma helps put better health within reach every day for
millions of people around the world. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the United States (US), the
Middle East and North Africa (MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,700 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSSFASUWEESEED
(END) Dow Jones Newswires
March 17, 2022 06:00 ET (10:00 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2024 to Jun 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2023 to Jun 2024